细胞因子
细胞因子释放综合征
细胞生物学
体内
化学
免疫学
生物
T细胞
免疫系统
嵌合抗原受体
遗传学
作者
Anett Pfeiffer,Frederic B. Thalheimer,Sylvia Hartmann,Annika M. Frank,Ruben R Bender,Simon Danisch,Caroline Costa,Winfried S. Wels,Ute Modlich,Renata Stripecke,Els Verhoeyen,Christian J. Buchholz
标识
DOI:10.15252/emmm.201809158
摘要
Chimeric antigen receptor (CAR) T cells brought substantial benefit to patients with B-cell malignancies.Notwithstanding, CAR T-cell manufacturing requires complex procedures impeding the broad supply chain.Here, we provide evidence that human CD19-CAR T cells can be generated directly in vivo using the lentiviral vector CD8-LV specifically targeting human CD8 + cells.Administration into mice xenografted with Raji lymphoma cells and human peripheral blood mononuclear cells led to CAR expression solely in CD8 + T cells and efficacious elimination of CD19 + B cells.Further, upon injection of CD8-LV into mice transplanted with human CD34 + cells, induction of CAR T cells and CD19 + B-cell depletion was observed in 7 out of 10 treated animals.Notably, three mice showed elevated levels of human cytokines in plasma.Tissue-invading CAR T cells and complete elimination of the B-lymphocyte-rich zones in spleen were indicative of a cytokine release syndrome.Our data demonstrate the feasibility of in vivo reprogramming of human CD8 + CAR T cells active against CD19 + cells, yet with similar adverse effects currently notorious in the clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI